|
Utilization and clinical impact of genomic profiling for EGFR and ALK in non-squamous non-small cell lung cancer (NSCLC) in the community setting. |
| |
|
Research Funding - Abbvie (Inst); Acceleron Pharma (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Esanex (Inst); Gilead Sciences (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); MedImmune (Inst); Novartis (Inst); Rexahn Pharmaceuticals (Inst); TG Therapeutics (Inst) |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Employment - Foundation Medicine |
| |
|
Employment - Foundation Medicine |
| |
|
No Relationships to Disclose |
| |
|
Employment - Cancer Outcomes Tracking and Analysis |
Leadership - Cancer Outcomes Tracking and Analysis |
Stock and Other Ownership Interests - Cancer Outcomes Tracking and Analysis |
| |
|
Employment - Cancer Outcomes Tracking and Analysis |
Leadership - Cancer Outcomes Tracking and Analysis |
Stock and Other Ownership Interests - Cancer Outcomes Tracking and Analysis |
| |
|
Leadership - Cancer Outcomes Tracking and Analysis |
Stock and Other Ownership Interests - Cancer Outcomes Tracking and Analysis |
| |
|
Employment - Cancer Outcomes Tracking and Analysis |
Leadership - Cancer Outcomes Tracking and Analysis |
Stock and Other Ownership Interests - Cancer Outcomes Tracking and Analysis |